Selective inhibition of FTO can break the AML1-ETO/FTO feedback loop, inhibit progression and resensitizes resistant cells to Ara-C, highlighting a great therapeutic potential for the efficacious small-molecule FTO inhibitors, in combination with routine chemotherapy, in the treatment of t(8;21) AML. Here, FTO is linked to acute myeloid leukemia.